期刊
THORAX
卷 71, 期 1, 页码 88-90出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2015-207983
关键词
-
资金
- Cystic Fibrosis Foundation
- European Cystic Fibrosis Society
- Wellcome Trust
- Cambridge NIHR BRC
- Intramural programme of the National Heart, Lung, and Blood Institute, NIH
- Vaincre La Mucoviscidose [VLMIC1014, RF20120600689]
- Region Ile-de-France Domaine d'Interet Majeur Maladies Infectieuses et Emergentes
- CF Foundation Clinical Research Award [NICK13A0]
- Imperial College London NIHR Respiratory BRU
- Cystic Fibrosis Trust [VIA025] Funding Source: researchfish
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006200] Funding Source: NIH RePORTER
Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with preexisting inflammatory lung disease, such as cystic fibrosis (CF). Pulmonary disease (PD) caused by NTM has emerged as a major threat to the health of individuals with CF, but remains difficult to diagnose and problematic to treat. In response to this challenge, the US Cystic Fibrosis Foundation (CFF) and the European Cystic Fibrosis Society (ECFS) convened a panel of 19 experts to develop consensus recommendations for the screening, investigation, diagnosis and management of NTM-PD in individuals with CF. PICO (population, intervention, comparison, outcome) methodology and systematic literature reviews were employed to inform draft recommendations, which were then modified to achieve consensus and subsequently circulated for public consultation within the USA and European CF communities. We have thus generated a series of pragmatic, evidence-based recommendations as an initial step in optimising management for this challenging condition.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据